Lee Chan Henry

Insider trading profile for Lee Chan Henry at BeOne Medicines Ltd. (ONC, 92 tx, 2023-2026, single-company insider): 100% A-code (award) + M-code (vest) + F-code (tax) pattern. Jun 2026: two large A-code awards totalling 132,379 shares: 87,308 at $20.81 FMV and 45,071 at $0 FMV; paired partial S-code monetization 428 at $257.64 + 160 + 711 at $271 = tiny fractions of new grants. Earlier: Mar 2026 A-code aggregate; Apr 2026 M-code vest batches (1,274 + 1,729 + 1,313 at $12-16 exercise) with S-code 332 at $311.59 + 98 at $159 + 133 at $213 + 101 at $194 = full monetization of each vesting tranche. Dec 2025 M 3-pack vesting at $0; May 2023 pattern. KEY SIGNAL: Pure grant-accept + immediate-profits cycle with zero retained personal capital in ONC. The A-code is awarded, then systematically sold at $257-$325 (a 12x-26x spread from $12-$20 cost), indicating the insider treats all vesting as income to monetize rather than conviction. BeOne is a SPAC'd biotech microcap where the insider holds zero personal open-market buy exposure. Classification: bearish -- the insider has provided zero discretionary buy-side conviction across the entire public life of the company; the vest-sell cycle is income extraction, not retention.